Webb28 dec. 2024 · This study was funded by Therachon AG, a wholly owned subsidiary of Pfizer. The funder provided support in the form of salaries for authors [DG, GR, PD, GH, … WebbTherachon Presents Data from Preclinical and Phase I clinical Studies of Apraglutide for the Treatment of Short Bowel Syndrome at ASPEN 2024 Nutrition Science & Practice …

EU grants Therachon Orphan Drug Designation

Webb5 sep. 2024 · U.S. pharmaceutical company Pfizer is acquiring Basel biotech Therachon for US$ 340 million. Additional payments of US$ 470 million may also be received on the achievement of key milestones. Therachon has developed a drug for the treatment of a form of short-limbed dwarfism. Drug discovery (img: motorolka_10/shutterstock) Webbför 2 dagar sedan · Therachon Holding AG is a privately held clinical-stage biotechnology company. Pfizer Inc. paid an additional USD 470 million for Therachon Holding AG, in addition to $340 million, under... slow mill sustainable power

Clinton Bourbonais - Executive Director, Corporate …

WebbTherachon is a global biotechnology company (headquartered in Basel) committed to making a difference in the lives of patients living with serious rare conditions. Therachon … WebbCo-founder, President and Chief Executive Officer Kathleen Sereda Glaub, MBA Co-founder and Executive Chair of the Board of Directors Gabriel Vargas, MD, PhD Chief Medical Officer Peter Butera Senior Vice President, Operations Renee Martin, PhD Vice President, Translational Science Distinguished Advisors Robert Booth, PhD Webb15 maj 2024 · Catalent has signed an agreement with Therachon AG to support development of TA-46 addressing achondroplasia, the most common form of short … software security requirements examples